RT Journal Article
SR Electronic
T1 Impact of an over-the-counter “sleep lotion” on salivary melatonin levels and sleep quality: a randomized controlled trial
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.10.16.23297058
DO 10.1101/2023.10.16.23297058
A1 Ponce, Clairissa
A1 Razon, Amanda D.
A1 Chao, Joey
A1 Nakagawa, Sydney K.
A1 Peterson, Megan M.
A1 Roque, Angelina Y.
A1 Vanderpool, Maya A.
A1 Ferracane, Michael J.
A1 Olson, Lisa E.
YR 2023
UL http://medrxiv.org/content/early/2023/10/19/2023.10.16.23297058.abstract
AB Many over-the-counter products such as bubble baths, room sprays, and lotions claim they contain the pineal hormone melatonin and promote sleep. In this randomized, controlled, double-blind crossover trial we compared the impact of a commercial “sleep lotion” versus a placebo control lotion. Our sample of 63 undergraduate college students scored an average of 6.3 ± 2.7 on the Global Pittsburgh Sleep Quality Index, with 65% above the cutoff of 5 indicating poor sleep quality in the previous 30 days. Participants applied lotions on two different nights, one hour before bedtime. To assess whether melatonin was absorbed through the skin and circulating systemically, we conducted enzyme linked immunosorbent assays on saliva samples to quantitate melatonin levels. We also assessed sleep quality the night after lotion application with a modified Pittsburgh Sleep Quality Index. The melatonin-containing sleep lotion dramatically impacted salivary melatonin levels, increasing them up to ∼1000 fold compared to the placebo control lotion. Sleep quality in the overall group was not impacted by the lotion, but in a subsample of the poor sleepers, the lotion improved sleep quality. High Performance Liquid Chromatography of the sleep lotion revealed the presence of 2.4 ± 0.1 mg melatonin/g lotion, or a 0.24 ± 0.01% formulation. Caution should be taken by consumers using over-the-counter melatonin lotions because the undisclosed dosage is high and well absorbed by the skin. Clinicaltrials.gov ID NCT06053385Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT06053385Funding StatementNo external funding was received for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of the University of Redlands gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.